Clinical Trial: Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363460) titled 'Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN' on Dec. 03, 2025.

Brief Summary: A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis

Study Start Date: Nov. 18, 2025

Study Type: INTERVENTIONAL

Condition: Lupus Nephritis (LN)

Intervention: DRUG: HSK39297 200mgQD

once daily, oral administration of HSK39297 tablets 200mg from Day 1 to Week 52.

DRUG: HSK39297 300mgQD

once daily, oral administration of HSK39297 tablets 300mg from Day 1 to W...